KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Gross Margin (2017 - 2025)

Historic Gross Margin for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to 81.95%.

  • Biomarin Pharmaceutical's Gross Margin rose 72200.0% to 81.95% in Q3 2025 from the same period last year, while for Sep 2025 it was 81.32%, marking a year-over-year increase of 24700.0%. This contributed to the annual value of 79.67% for FY2024, which is 16600.0% up from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Gross Margin stood at 81.95%, which was up 72200.0% from 81.82% recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Gross Margin registered a high of 81.95% during Q3 2025, and its lowest value of 72.72% during Q4 2022.
  • Over the past 5 years, Biomarin Pharmaceutical's median Gross Margin value was 77.48% (recorded in 2022), while the average stood at 77.71%.
  • In the last 5 years, Biomarin Pharmaceutical's Gross Margin surged by 142700bps in 2021 and then crashed by -32500bps in 2024.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Gross Margin stood at 73.38% in 2021, then decreased by -1bps to 72.72% in 2022, then grew by 8bps to 78.66% in 2023, then rose by 4bps to 81.78% in 2024, then grew by 0bps to 81.95% in 2025.
  • Its last three reported values are 81.95% in Q3 2025, 81.82% for Q2 2025, and 79.66% during Q1 2025.